RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
477 articles about RedHill Biopharma
-
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
8/23/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the U.S. Patent and Trademark Office has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029.
-
RedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
8/19/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will report its second quarter 2021 financial results and operational highlights on Thursday, August 26, 2021.
-
Clinical Catch-Up: July 19-23
7/26/2021
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more. -
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
7/22/2021
RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.
-
RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
7/20/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that OptumRx, part of the UnitedHealth Group - a leader in healthcare coverage, partnered with more than 1.3 million healthcare professionals and 6,500 hospitals, has added Talicia® [1] to its Commercial Formulary as an unrestricted brand for H. pylori treatment, effective July 1, 2021.
-
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib
7/19/2021
RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib [1] in patients hospitalized with severe COVID-19 pneumonia.
-
RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans
7/13/2021
Movantik® included as preferred brand with no restrictions on a National Formulary of one of America's largest payors as of July 1st 2021
-
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study
6/28/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib.
-
Although the COVID-19 pandemic is waning in the U.S., it’s not completely over and there are some concerns, particularly with the delta variant, which originated in India. Here’s a look.
-
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
6/21/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib [1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum 2021.
-
Clinical Catch-Up: June 7-11
6/14/2021
A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more. -
RedHill Biopharma to Present at the BIO Digital International Convention
6/9/2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Adi Frish, RedHill's Chief Corporate & Business Development Officer, will present a corporate overview at the BIO Digital International Convention, taking place June 14-18, 2021.
-
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
6/7/2021
The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more than the planned 464
-
RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
5/27/2021
Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance[i] of approximately $92 million as of March 31, 2021, compared to approximately $115 million as of March 31, 2020
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021
5/24/2021
Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement of Movantik for a broad range of challenging opioid-induced constipation (OIC) symptoms
-
RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021
5/21/2021
New Travelers' Diarrhea (TD) severity classification tool, developed with the University of Texas Houston School of Public Health, provides clear separation of clinical severity categories and prognostic information for TD resolution with potential utility in clinical practice
-
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021
5/20/2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2021 financial results and operational highlights on Thursday, May 27, 2021 .
-
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.